US FDA issues new citizen petition guidelines
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued a new guidance document for drug makers filing a citizen petition seeking to stay actions on a pending abbreviated new drug application (ANDA) or a 505(b)(2) application1.